ArticleFrontiers in molecular biosciences2026
Integrating multi-omics, machine learning, and molecular dynamics simulations to identify glutamate metabolism-related biomarkers and drug candidates in rheumatoid arthritis.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder marked by progressive joint destruction and functional impairment. Increasing data indicate that glutamate metabolism is critically involved in RA pathogenesis. This analysis aimed to identify glutamate metabolism-related biomarkers and potential RA therapeutics. Methods: Integrated analysis of data sourced from the GeneCards and Gene Expression Omnibus databases detected differentially expressed glutamate metabolism genes (DEGMGs). Functional enrichment analysis was implemented. Weighted gene co-expression network analysis and three machine learning algorithms were combined to detect potential RA biomarkers. Immune infiltration characteristics were evaluated via the CIBERSORT algorithm. Single-cell RNA sequencing delineated the cellular localization of biomarkers. Molecular docking and dynamics simulations screened for small-molecule drugs. Finally, quantitative real-time polymerase chain reaction and Western blot experiments in a fibroblast-like synoviocyte model verified the expression levels of detected biomarkers. Results: This analysis identified 322 DEGMGs. Enrichment analysis revealed their involvement in biological processes, including the tumor necrosis factor, phosphatidylinositol 3-kinase-Akt, and Janus kinase-signal transducer and activator of transcription signaling pathways. Machine learning algorithms ultimately pinpointed four core biomarkers. Combined molecular docking and dynamics simulations revealed favorable binding between azacitidine and the target proteins, characterized by high affinity and complex stability. Conclusion: This study identified four glutamate metabolism-related genes-CXCL10, ENTPD1, GPX3, and PSMB9-as potential biomarkers for RA. Azacitidine was also predicted as having therapeutic potential for RA. Together, these findings advance the understanding of RA pathogenesis and provide a novel theoretical foundation and candidate targets for its clinical diagnosis and targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.